At the European Society for the Study of Diabetes (EASD) Annual Meeting in Barcelona, it was a pleasure to meet Jose Juanatey to discuss the latest insights in making guideline-directed treatment decisions in everyday practice.
1. How can we optimise patient involvement in therapeutic decision making? (0:05)
2. What are the most important factors to consider when considering treatment intensification beyond metformin? (1:40)
3. How have the findings of recent cardiovascular outcomes trials affected treatment decisions in patients with T2D? (3:30)
4. Which patients are most likely to benefit from SGLT2 inhibitors? (4:50)
What are the major talking points at this year’s EASD meeting? (6:24)
Jose Juanatey has no conflicts of interest to declare in relation to this video.
Filmed at the Annual Meeting of the European Association of the Study of Diabetes (EASD) Barcelona, Spain 2019.
Share this Video
Related Videos In Cardiovascular Risk
Peter Rossing, EASD 2022: The Relationship Between Cardiovascular and Renal Risks in Diabetes
Diabetes increases the risk of cardiovascular (CV) and renal disease (CVRD). These become major causes of mortality in individuals with diabetes. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University of Copenhagen, Copenhagen, Denmark) discusses the relationship between cardiovascular and renal risks in diabetes The abstract entitled: ‘Effect of semaglutide on MACE by baseline kidney function in participants […]
Peter Rossing, EASD 2022: The Effect of Semaglutide on Risk of MACE by Baseline Kidney Function: SUSTAIN 6 and PIONEER 6 Post Hoc Analysis
SUSTAIN 6 and PIONEER 6 investigated the effects of semaglutide versus placebo on major adverse cardiovascular events (MACE). The current post hoc analysis investigated the association between baseline kidney function and risk of MACE, and the effect of semaglutide on risk of MACE by baseline kidney function. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University […]
Hertzel Gerstein, ADA 2022: The ELIXA biomarker study, protein biomarkers to identify cardiovascular outcomes in patients with type 2 diabetes and acute coronary syndrome
The ELIXA biomarker study evaluated protein biomarkers as clinical risk factors to identify people with type 2 diabetes and acute coronary syndrome who are at highest risk for cardiovascular (CV) outcomes and death. Professor Hertzel Gerstein (McMaster University, Hamilton, ON, Canada) discusses the outcomes of the ELIXA biomarker study and the implications of the findings […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!